World's Best Scientists 2026 revealed!
Kazuhiko Nakagawa

Kazuhiko Nakagawa

Award Badge
Medicine
Japan
2023

D-Index & Metrics

Medicine

D-Index
116
Citations
71814
World Ranking
4275
National Ranking
88

Research.com Recognitions

  • 2023 - Research.com Medicine in Japan Leader Award

Overview

Kazuhiko Nakagawa is affiliated with Kindai University in Japan and has an extensive research portfolio primarily in the field of Medicine. Their work spans several subfields including Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Surgery, and Molecular Biology.

Their research focuses on major topics within oncology and respiratory medicine, such as:

  • Lung Cancer Treatments and Mutations
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Diagnosis and Treatment
  • Colorectal Cancer Treatments and Studies
  • Lung Cancer Research Studies
  • Cancer Genomics and Diagnostics
  • Gastric Cancer Management and Outcomes

Kazuhiko Nakagawa has coauthored papers frequently with the following researchers:

  • Nobuyuki Yamamoto (110 joint publications)
  • Hidetoshi Hayashi (84 joint publications)
  • Kazuto Nishio (55 joint publications)
  • Kazuko Sakai (41 joint publications)
  • Yasutaka Chiba (40 joint publications)

The scientist has contributed numerous articles to the following publication venues:

  • Annals of Oncology (37 publications)
  • Journal of Clinical Oncology (25 publications)
  • Journal of Thoracic Oncology (23 publications)
  • JTO Clinical and Research Reports (16 publications)
  • Lung Cancer (11 publications)

Among the noted recent papers authored are:

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study (2020, The Lancet Oncology)
  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer (2021, New England Journal of Medicine)
  • Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial (2022, The Lancet Oncology)
  • Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer (2020, JAMA Oncology)
  • Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE-158 and KEYNOTE-028 studies (2020, International Journal of Cancer)

Kazuhiko Nakagawa also has contributions to academic literature through book publications, including a title on environmental ecology:

  • Ecología, medio ambiente y sustentabilidad (2023), published by Universidad Nacional Autónoma de México, Secretaría de Desarrollo Institucional eBooks

Best Publications

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

    Masahiro Fukuoka;Seiji Yano;Giuseppe Giaccone;Tomohide Tamura

  • Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

    Tetsuya Mitsudomi;Satoshi Morita;Yasushi Yatabe;Shunichi Negoro

  • First-line crizotinib versus chemotherapy in ALK-positive lung cancer

    Benjamin J. Solomon;Tony Shu-kam Mok;Dong Wan Kim;Yi Long Wu

  • Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.

    Aurélien Marabelle;Marwan Fakih;Juanita Lopez;Manisha Shah

  • Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

    Masahiro Fukuoka;Yi Long Wu;Sumitra Thongprasert;Patrapim Sunpaweravong

  • Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

    Yi-Long Wu;Ying Cheng;Xiangdong Zhou;Ki Hyeong Lee

  • Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer.

    Koji Haratani;Hidetoshi Hayashi;Yasutaka Chiba;Keita Kudo

  • Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

    Takashi Seto;Terufumi Kato;Makoto Nishio;Koichi Goto

  • Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan

    Y Ohe;Y Ohashi;K Kubota;T Tamura

  • Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

    Toyoaki Hida;Hiroshi Nokihara;Masashi Kondo;Young Hak Kim

  • Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

    Kimio Yonesaka;Kreshnik Zejnullahu;Isamu Okamoto;Taroh Satoh

  • CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

    Thanyanan Reungwetwattana;Kazuhiko Nakagawa;Byoung Chul Cho;Manuel Cobo

  • CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

    Takashi Seto;Katsuyuki Kiura;Makoto Nishio;Kazuhiko Nakagawa

  • CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer.

    Noriyuki Masuda;Masahiro Fukuoka;Yoko Kusunoki;Kaoru Matsui

  • Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer.

    Bob T Li;Egbert F Smit;Yasushi Goto;Kazuhiko Nakagawa

  • Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Kazuhiko Nakagawa;Edward B Garon;Takashi Seto;Makoto Nishio

  • Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

    Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  • Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

    Riichiroh Maruyama;Yutaka Nishiwaki;Tomohide Tamura;Nobuyuki Yamamoto

  • Phase III Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904)

    Shinzoh Kudoh;Koji Takeda;Kazuhiko Nakagawa;Minoru Takada

Frequent Co-Authors

Isamu Okamoto
Isamu Okamoto Kyushu University
Kazuto Nishio
Kazuto Nishio Kindai University
Masahiro Fukuoka
Masahiro Fukuoka Kindai University
Tomohide Tamura
Tomohide Tamura St. Luke's International Hospital
Yuichiro Ohe
Yuichiro Ohe National Cancer Centre
Nagahiro Saijo
Nagahiro Saijo AstraZeneca (United Kingdom)
Satoshi Morita
Satoshi Morita Kyoto University
Tetsuya Mitsudomi
Tetsuya Mitsudomi Kindai University
Tony Mok
Tony Mok Chinese University of Hong Kong
Yi-Long Wu
Yi-Long Wu Guangdong Provincial People’s Hospital

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a future in Medicine or related healthcare fields, online degrees offer flexible, diverse career options beyond traditional medical school routes. Healthcare administration is one popular path, with several accredited mha programs available online. These programs equip graduates for leadership roles in hospitals and healthcare organizations.

Nursing professionals also benefit from streamlined online education. For RNs looking to advance, there are rn to bsn without clinicals programs, making it easier to earn a BSN while balancing work and life commitments.

Those aiming for the highest levels of nursing practice can explore the fastest online dnp programs for rapid career advancement. If flexibility and manageable workloads are your priority, consider the easiest dnp programs.

These online degrees open doors to specialized roles in patient care, administration, and leadership, making them valuable alternatives and complements to studying Medicine in the USA.

Best Scientists Citing Kazuhiko Nakagawa

Trending Scientists